Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.


Journal

The Journal of general virology
ISSN: 1465-2099
Titre abrégé: J Gen Virol
Pays: England
ID NLM: 0077340

Informations de publication

Date de publication:
05 2021
Historique:
entrez: 27 5 2021
pubmed: 28 5 2021
medline: 12 8 2021
Statut: ppublish

Résumé

Serum antibody levels can be used to measure the humoral immune response against human papillomaviruses (HPV). We developed and validated a rapid, technically simple and relatively inexpensive multiplex non-competitive Luminex-based immunoassay (ncLIA) to measure total IgG antibody levels against four HPV types. For the assay's solid phase, virus-like particles (VLPs) of HPV6, 11, 16 and 18 were bound to heparin-coated beads. HPV serum antibody levels binding to the VLPs were quantified using a phycoerithrin-conjugated secondary polyclonal donkey anti-human IgG antibody. Standardization and validation of the ncLIA were performed using 96 paired serum and genital samples from participants in the HITCH cohort study, including young women (aged 18-24 years) and their male sexual partners (aged 18+) in Montreal, Canada. Results from the ncLIA were compared to a validated Luminex immunoassay from PPD laboratories using Pearson's correlation coefficients, receiver operating characteristic curves and logistic regression. Our assay had good inter- and intra-assay variability. The correlation of serum antibody levels between the ncLIA and validation assay was highest for HPV16 and HPV11 (

Identifiants

pubmed: 34043499
doi: 10.1099/jgv.0.001610
pmc: PMC8627678
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI073889
Pays : United States

Références

Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Lancet Oncol. 2012 Jan;13(1):89-99
pubmed: 22075171
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
J Gen Virol. 2010 Jul;91(Pt 7):1840-8
pubmed: 20181747
Curr Protoc Cell Biol. 2007 Dec;Chapter 26:Unit 26.1
pubmed: 18228512
Hum Vaccin Immunother. 2014;10(8):2168-74
pubmed: 25424920
BMC Infect Dis. 2016 Sep 22;16(1):502
pubmed: 27659061
Clin Vaccine Immunol. 2012 Sep;19(9):1348-52
pubmed: 22761294
Hum Vaccin Immunother. 2014;10(10):2965-74
pubmed: 25483632
Cancer Discov. 2011 Oct;1(5):408-19
pubmed: 22586631
Hum Vaccin Immunother. 2014;10(8):2438-45
pubmed: 25424952
Clin Vaccine Immunol. 2010 May;17(5):818-27
pubmed: 20237197
J Infect Dis. 2016 May 1;213(9):1444-54
pubmed: 26690341
Vaccine. 2012 Nov 20;30 Suppl 5:F123-38
pubmed: 23199956
N Engl J Med. 2007 May 10;356(19):1915-27
pubmed: 17494925
PLoS One. 2013;8(1):e53067
pubmed: 23301022
Front Oncol. 2014 Jan 13;3:328
pubmed: 24455487
Virology. 2004 Apr 10;321(2):205-16
pubmed: 15051381
Hum Vaccin Immunother. 2015;11(3):732-8
pubmed: 25714044
N Engl J Med. 2007 May 10;356(19):1928-43
pubmed: 17494926
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
EClinicalMedicine. 2020 Apr 07;21:100334
pubmed: 32382718
J Med Virol. 2014 Sep;86(9):1542-55
pubmed: 24895216
Virology. 2013 Oct;445(1-2):169-74
pubmed: 23800545
JMIR Res Protoc. 2019 Jan 16;8(1):e11284
pubmed: 30650383
Hum Vaccin. 2011 Feb;7(2):230-8
pubmed: 21307649
J Virol. 2006 May;80(10):4664-72
pubmed: 16641259
Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69
pubmed: 16085914
Hum Vaccin. 2008 Nov-Dec;4(6):425-34
pubmed: 18948732
Clin Diagn Lab Immunol. 2003 Jan;10(1):108-15
pubmed: 12522048
J Infect Dis. 1995 Dec;172(6):1425-30
pubmed: 7594698
J Immunol Methods. 2015 Feb;417:107-114
pubmed: 25554636
J Clin Microbiol. 2006 Jun;44(6):1998-2006
pubmed: 16757590
Methods Mol Med. 2005;119:445-62
pubmed: 16350417
J Virol. 2004 Jan;78(2):751-7
pubmed: 14694107
Vaccine. 2012 Nov 20;30 Suppl 5:F175-82
pubmed: 23199961

Auteurs

Andrea Trevisan (A)

Laboratoire de santé publique du Québec, Institut national de santé publique Québec, 20045 Sainte-Marie Road, Sainte-Anne-de-Bellevue, Quebec, Canada.
Sainte-Justine Hospital Research Center, Université de Montréal, 3175 Côte Sainte-Catherine, Montreal, Quebec, Canada.

Michel D Wissing (MD)

Division of Cancer Epidemiology, McGill University, 5100 Boulevard de Maisonneuve West, Suite 720, Quebec H4A 3T2, Montreal, Canada.

Carole Dagenais (C)

Laboratoire de santé publique du Québec, Institut national de santé publique Québec, 20045 Sainte-Marie Road, Sainte-Anne-de-Bellevue, Quebec, Canada.

Pierre Forest (P)

Laboratoire de virologie moléculaire, centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), 900 Saint Denis Street, Montreal, Quebec H2X 0A9, Canada.

Agnihotram V Ramanakumar (AV)

Division of Cancer Epidemiology, McGill University, 5100 Boulevard de Maisonneuve West, Suite 720, Quebec H4A 3T2, Montreal, Canada.

Ann N Burchell (AN)

Department of Family and Community Medicine and MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 30 Bond Street, Toronto M5B 1T8, Ontario.

Eduardo L Franco (EL)

Division of Cancer Epidemiology, McGill University, 5100 Boulevard de Maisonneuve West, Suite 720, Quebec H4A 3T2, Montreal, Canada.

François Coutlée (F)

Laboratoire de virologie moléculaire, centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), 900 Saint Denis Street, Montreal, Quebec H2X 0A9, Canada.

Michel Couillard (M)

Laboratoire de santé publique du Québec, Institut national de santé publique Québec, 20045 Sainte-Marie Road, Sainte-Anne-de-Bellevue, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH